Advertisement

Topics

FDA approves pegfilgrastim biosimilar for infection in cancer patients

04:54 EST 9 Nov 2018 | SmartBrief

Coherus BioSciences' Udenyca, or pegfilgrastim-cbqv, has gained FDA approval as a pegfilgrastim biosimilar of Amgen's Neulast -More

Original Article: FDA approves pegfilgrastim biosimilar for infection in cancer patients

NEXT ARTICLE

More From BioPortfolio on "FDA approves pegfilgrastim biosimilar for infection in cancer patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...